Vascular Access Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Vascular Access Devices Market Trends and Insights

Rising burden of chronic diseases & high IV-therapy demand

Chronic conditions such as diabetes and heart failure are driving long-term intravenous treatment requirements worldwide. Home infusion now serves more than 3.2 million Americans annually, with spending exceeding USD 110 billion and rising 5-7% each year. Durable midline catheters and extended-dwell peripheral devices lower complication risk, supporting broader outpatient management. Hydrophilic biomaterials like Access Vascular’s MIMIX reduce failure rates and can save a 1,000-bed hospital USD 1.8 million a year. These economics elevate vascular access devices from commodity supplies to essential infrastructure.

Growth in chemotherapy procedures & hospitalization

Personalized oncology regimens increasingly depend on central venous catheters that tolerate vesicant drugs while permitting frequent sampling ^{[1]Caitriona Duggan, "Vascular access devices for prolonged intravenous therapy regimens in people diagnosed with cancer," Cohrane Library, pmc.ncbi.nlm.nih.gov}. Peripherally inserted central catheters (PICCs) improve outpatient flexibility, cutting treatment delays and hospital stays. Chlorhexidine-impregnated dressings have trimmed bloodstream infections by 52% in trials, underpinning premium pricing for infection-resistant devices ^{[2]Huilin Xu, "Improving central venous catheter care with chlorhexidine gluconate dressings: evidence from a systematic review and Meta-analysis," BMC, jhpn.biomedcentral.com}.

Increasing pediatric & neonatal vascular access

Neonatal intensive care units report 4-day average indwell times for extended-dwell peripheral IVs with 71.7% success, while PICCs reach 83.6%. The modified Seldinger technique minimizes vessel trauma in premature infants. Taurolidine locks cut bloodstream infections by 45% and hospitalizations by 41% in children on parenteral nutrition. Pediatric-specific R&D therefore remains a strategic differentiator.

Adoption of ultrasound-guided DIVA solutions

Difficult intravenous access affects up to 35% of surgical patients, costing U.S. emergency departments USD 2.68 billion annually. Ultrasound triples first-attempt success, yet two-thirds of clinicians still rely on blind cannulation. One-hand guidewire kits achieve 75% first-try success versus 50% for standard methods. Vendors pairing catheters with bedside imaging and training capture outsized mindshare ^{[3]Amit Bahl, "An Improved Definition and SAFE Rule for Predicting Difficult Intravascular Access (DIVA) in Hospitalized Adults," Journal of Infusion Nursing, journals.lww.com}.

Catheter-associated bloodstream infections (CLABSI)

Intensive-care units still record 4.9 infections per 1,000 catheter days, with every episode adding treatment cost and mortality risk. Digital dashboards cut CLABSI rates by up to 73% but require capital investment. Chlorhexidine dressings reduce catheter colonization by 54%. Hospitals consequently favor integrated infection-control bundles, squeezing commodity vendors that lack advanced coatings.

Stringent regulatory scrutiny & product recalls

FDA alerts on catheter material fatigue and its harmonized Quality System Regulation demand costly redesigns that smaller firms struggle to meet. New 506J shortage-notification rules compel manufacturers to disclose supply disruptions six months ahead, exposing competitive information. The compliance burden accelerates consolidation in the vascular access devices market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Device Type: Central Dominance with Peripheral Momentum

Central devices captured 56.12% of vascular access devices market share in 2025. PICCs remain the workhorse for oncology and critical-care settings, whereas tunneled catheters support year-long therapies. Hospitals value their reliable flow and lower reinsertion frequency, even as reimbursement pressures intensify scrutiny of infection risk and dwell time.

Peripheral catheters, however, are the fastest-growing class at a 7.61% CAGR. Extended-dwell designs bridge the gap between standard PIVCs and PICCs, reducing cost and complication rates for intermediate therapies. FDA-cleared devices such as B. Braun’s Introcan Safety 2 extend median dwell to 5.7 days. Ultrasound-guided placement has broadened clinical acceptance, and antimicrobial polyurethane upgrades further differentiate offerings. As outpatient infusion volumes swell, peripheral innovations are positioned to gain additional vascular access devices market traction.

By Application: Therapeutic Delivery Leads, Diagnostics Accelerates

Medication administration commanded 39.55% of 2025 revenue, underlining the indispensable role of safe intravenous drug delivery. Complex biologics, chemotherapy cocktails and high-osmolar solutions necessitate robust central lines and ports capable of repeated access without integrity loss. Coated lumens and pressure-tolerant hubs have become standard, supporting price premiums.

Diagnostics and testing is forecast to grow at a 7.68% CAGR as precision-medicine protocols demand serial biomarker sampling. Point-of-care devices shorten turnaround times, spurring hospitals to favor catheters with low hemolysis rates and easy blood-draw access. Manufacturers integrating multi-lumen configurations and AI-optimized geometries offer tangible workflow savings, strengthening competitive positioning within the vascular access devices market.

By End User: Hospitals Retain Scale, ASCs Gain Velocity

Hospitals and clinics generated 52.90% of 2025 revenue because critical-care, emergency and surgical departments rely on high-performance vascular access platforms. Large networks negotiate bulk contracts that bundle catheters with integrated securement and antimicrobial accessories. Supply-chain shocks have led many systems to dual-source, allowing nimble suppliers to unseat incumbents.

ASCs represent the fastest-expanding channel with an 7.77% CAGR through 2031. Newly introduced C-codes lift reimbursement for cardiac catheterization by up to USD 3,346, validating same-day procedural economics. Private-equity backed ASC chains are scaling cardiology and vascular suites, elevating demand for user-friendly kits that speed turnover. Vendors re-engineering packaging for quick procedural setup are poised to capture incremental vascular access devices market sales.

By Material: Polyurethane Foundation, Silicone Upswing

Polyurethane held 48.25% share in 2025, reflecting decades of clinical familiarity and cost efficiency. Yet the material’s 30% complication rate in catheter cases drives hospitals to seek alternatives. Tight medical-grade PU supply following PTFE shortages has prompted larger firms to verticalize extrusion or lock in long-term contracts, buffering margin impact.

Silicone, advancing at an 7.85% CAGR, benefits from superior biocompatibility that lowers thrombosis. Surface-modified silicone infused with antimicrobial agents slashes bacterial adhesion and meets long-term implant needs. Pediatric specialists increasingly specify silicone lines for fragile vessels, making the material a strategic focus area. Hybrid constructs—combining silicone flexibility with polyurethane strength—are emerging, reinforcing material innovation as a core battleground in the vascular access devices market.

Geography Analysis

North America commanded 39.85% of 2025 revenue on the back of sophisticated healthcare infrastructure and an insurance mix that rewards infection-reduction technologies. BD invested more than USD 10 million in 2024 to expand U.S. catheter production, adding hundreds of millions of units annually and reinforcing domestic supply resilience. Terumo earmarked USD 30 million for Angio-Seal capacity in Puerto Rico, underscoring the region’s manufacturing pull.

Asia-Pacific is projected to post an 7.95% CAGR through 2031, reflecting rising chronic disease prevalence and healthcare spending. China’s shift to value-based procurement is exerting price pressure, yet local champions eye export markets to offset domestic margin compression. Japan-headquartered Terumo reported that its Rika mid-clamp platform is now installed in 98 centers across the region, nearing its 100-site milestone.

Europe maintains a robust installed base driven by strict infection-prevention mandates and early HTA adoption. Meanwhile, Middle Eastern health-system build-outs and South American economic recovery create pockets of high growth, especially where public insurers support outpatient infusion. Ongoing geopolitical frictions and raw-material constraints are encouraging firms to develop multi-hub sourcing models so the vascular access devices market can meet varied regional demand without disruption.

Regulatory Landscape

Vascular access devices are regulated as medical devices across major markets, with U.S. requirements centered on FDA device classification and quality system compliance for design, manufacturing, and post-market controls (including device types covered under 21 CFR 876.5540 for blood access devices). FDA scrutiny has increasingly focused on material performance and reliability in catheter systems, alongside broader U.S. policy attention to medical device oversight and supply continuity. This is raising expectations for documentation, risk management, and change control across incumbent portfolios and line extensions.

In Europe, Regulation (EU) 2017/745 (MDR) continues to shape clinical evidence and conformity assessment pathways for catheters and implantable access solutions, influencing timelines and the role of notified bodies. In March 2026, the European Commission adopted Delegated Regulation (EU) 2026/1451, updating the list of implantable and class III devices exempted from mandatory clinical investigations, and providing targeted clarity for certain catheter, cannula, and introducer categories. In Canada, Health Canada has continued modernizing medical device licensing processes, including an April 2026 shift to mandatory use of its regulatory enrolment process, reinforcing the move toward standardized, structured submissions.

Market Opportunities and Future Outlook

Procurement is shifting away from standalone commodity catheters toward integrated insertion and workflow systems that reduce steps, limit contamination opportunities, and standardize technique in high-volume settings. A concrete proof point is BD's April 2026 commercial launch of the CentroVena One Insertion System (following FDA 510(k) clearance and FDA Safer Technologies Program acceptance), along with its June 2026 Innovative Technology contract award from Vizient, which supports faster access within provider networks focused on measurable efficiency and safety improvements. This direction creates whitespace for vendors that bundle device, insertion components, and training into standardized kits aligned with ultrasound-guided practice and difficult IV access protocols.

Material innovation is another opportunity area, particularly for long-dwell performance in chronic therapy and dialysis, where infection and thrombosis concerns support differentiation and total-cost arguments. In July 2026, Xeltis initiated European commercialization of its aXess vascular access device for hemodialysis, with a first commercial patient treatment at Artemed Klinikum Munich South, illustrating active translation of restorative biomaterial concepts into clinical use. Commercial scaling also depends on distribution leverage, illustrated by Access Vascular's multi-year co-branding and distribution agreement with Medline for HydroMID and HydroPICC catheters. Regulatory expectations further reinforce usability-led design, since FDA's May 2026 final guidance on human factors information in device marketing submissions raises the bar for risk-based usability evidence and rewards companies that embed human factors engineering earlier in development.